Top

Published in:

Open Access 01-03-2012

Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome

Authors: Suzan Willemsen, Jasper W. L. Hartog, M. Rebecca Heiner-Fokkema, Dirk J. van Veldhuisen, Adriaan A. Voors

Published in: Heart Failure Reviews | Issue 2/2012

Abstract

The prevalence of heart failure (HF) is increasing. A distinction is made between diastolic HF (preserved left ventricular ejection fraction (LVEF)) and systolic HF (reduced LVEF). Advanced glycation end-products (AGEs) are crystallized proteins that accumulate during ageing, but are particularly increased in patients with diabetes mellitus and in patients with renal failure. Through the formation of collagen crosslinks, and by interaction with the AGE-receptor, which impairs calcium handling and increases fibrosis, AGE-accumulation has pathophysiologically been associated with the development of diastolic and renal dysfunction. Interestingly, diastolic dysfunction is a frequent finding in elderly patients, diabetic patients and in patients with renal failure. Taken together, this suggests that AGEs are related to the development and progression of diastolic HF and renal failure. In this review, the role of AGEs as a possible pathophysiological factor that link the development and progression of heart and renal failure, is discussed. Finally, the role of AGE intervention as a possible treatment in HF patients will be discussed.

Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Bohm M, Corra U, della Bella P, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zamorano JL, Zannad F (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10:933–989PubMedCrossRef

Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB Sr (2006) Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 113:2914–2918PubMedCrossRef

Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260–269PubMedCrossRef

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259PubMedCrossRef

Zile MR, Baicu CF, Gaasch WH (2004) Diastolic heart failure–abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350:1953–1959PubMedCrossRef

Kamalesh M, Subramanian U, Sawada S, Eckert G, Temkit M, Tierney W (2006) Decreased survival in diabetic patients with heart failure due to systolic dysfunction. Eur J Heart Fail 8:404–408PubMedCrossRef

Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC (1996) Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 77:1017–1020PubMedCrossRef

Ezekowitz JA, Lee DS, Tu JV, Newman AM, McAlister FA (2008) Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%. Am J Cardiol 102:79–83PubMedCrossRef

Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB (2007) Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50:768–777PubMedCrossRef

10.

Philbin EF, Weil HF, Francis CA, Marx HJ, Jenkins PL, Pearson TA, Reed RG (2000) Race-related differences among patients with left ventricular dysfunction: observations from a biracial angiographic cohort. J Card Fail 6:187–193PubMedCrossRef

11.

Tribouilloy C, Rusinaru D, Mahjoub H, Tartiere JM, Kesri-Tartiere L, Godard S, Peltier M (2008) Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart 94:1450–1455PubMedCrossRef

12.

Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ (2007) Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 9:1146–1155PubMedCrossRef

13.

Miyata T, Sugiyama S, Saito A, Kurokawa K (2001) Reactive carbonyl compounds related uremic toxicity (“carbonyl stress”). Kidney Int Suppl 78:S25–S31PubMedCrossRef

14.

Willemsen S, Hartog JW, Hummel YM, van Ruijven MH, van der Horst IC, van Veldhuisen DJ, Voors AA (2011) Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail 13:76–82PubMedCrossRef

15.

Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17:2034–2047PubMedCrossRef

16.

Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House A, Katz NM, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P (2010) Cardiorenal syndromes: an executive summary from the consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 165:54–67PubMedCrossRef

17.

Alpert MA (2003) Cardiac performance and morphology in end-stage renal disease. Am J Med Sci 325:168–178PubMedCrossRef

18.

Hartog JW, Hummel YM, Voors AA, Schalkwijk CG, Miyata T, Huisman RM, Smit AJ, van Veldhuisen DJ (2008) Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 14:596–602PubMedCrossRef

19.

Rakhit DJ, Zhang XH, Leano R, Armstrong KA, Isbel NM, Marwick TH (2007) Prognostic role of subclinical left ventricular abnormalities and impact of transplantation in chronic kidney disease. Am Heart J 153:656–664PubMedCrossRef

20.

Virga G, Stomaci B, Munaro A, Mastrosimone S, Cara M, Artuso E, Piovesana P (2006) Systolic and diastolic function in renal replacement therapy: a cross-sectional study. J Nephrol 19:155–160PubMed

21.

Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL (2007) Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13:599–608PubMedCrossRef

22.

23.

24.

Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53:582–588PubMedCrossRef

25.

Smit AJ, Gerrits EG (2010) Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 19:527–533PubMedCrossRef

26.

Schalkwijk CG, Baidoshvili A, Stehouwer CD, van HV, Niessen HW (2004) Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta 1636:82–89PubMed

27.

Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:457–468PubMedCrossRef

28.

Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al Abed Y, Vlassara H, Bucala R, Cerami A (1997) Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 94:13915–13920PubMedCrossRef

29.

Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14:728–731PubMedCrossRef

30.

Teerlink T, Barto R, Ten Brink HJ, Schalkwijk CG (2004) Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 50:1222–1228PubMedCrossRef

31.

Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG (2009) Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 877:610–614PubMedCrossRef

32.

Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ (2004) Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47:1324–1330PubMedCrossRef

33.

Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46:223–234PubMedCrossRef

34.

Loimaala A, Groundstroem K, Rinne M, Nenonen A, Huhtala H, Vuori I (2007) Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes. Cardiovasc Ultrasound 5:32–40PubMedCrossRef

35.

Smit AJ, Hartog JW, Voors AA, van Veldhuisen DJ (2008) Advanced glycation endproducts in chronic heart failure. Ann N Y Acad Sci 1126:225–230PubMedCrossRef

36.

Wu YW, Hsu CL, Wang SS, Tsai MW, Chu SH, Chen YS, Yang WS, Wu YT (2008) Impaired exercise capacity in diabetic patients after coronary bypass surgery: effects of diastolic and endothelial function. Cardiology 110:191–198PubMedCrossRef

37.

Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884PubMedCrossRef

38.

Lindsey JB, Cipollone F, Abdullah SM, McGuire DK (2009) Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res 6:7–14PubMedCrossRef

39.

Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L, Moure-Gonzalez M, Seoane-Blanco A, Varela-Roman A, Alvarez E, Gonzalez-Juanatey JR (2010) Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: new roles for soluble RAGE. Eur J Heart Fail 12:1092–1100PubMedCrossRef

40.

Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK (2009) Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the dallas heart study. Diabetes Care 32:1218–1220PubMedCrossRef

41.

Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037PubMedCrossRef

42.

Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 2010;PMID:20957395

43.

Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348:2007–2018PubMedCrossRef

44.

Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105:1387–1393PubMedCrossRef

45.

Moreo A, Ambrosio G, De Chiara B, Pu M, Tran T, Mauri F, Raman SV (2009) Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo. Circ Cardiovasc Imaging 2:437–443PubMedCrossRef

46.

Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, Bakker SJ, Smit AJ, van Veldhuisen DJ (2007) Clinical and prognostic value of advanced glycationend-products in chronic heart failure. Eur Heart J 28:2879–2885PubMedCrossRef

47.

Kass DA, Bronzwaer JG, Paulus WJ (2004) What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 94:1533–1542PubMedCrossRef

48.

Zieman SJ, Kass DA (2004) Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64:459–470PubMedCrossRef

49.

Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 105:1503–1508PubMedCrossRef

50.

Schafer S, Huber J, Wihler C, Rutten H, Busch AE, Linz W (2006) Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-(carboxymethyl) lysine. Eur J Heart Fail 8:2–6PubMedCrossRef

51.

Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H (2002) Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34:1425–1431PubMedCrossRef

52.

Cowburn PJ, Cleland JG, Coats AJ, Komajda M (1998) Risk stratification in chronic heart failure. Eur Heart J 19:696–710PubMedCrossRef

53.

Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52:818–827PubMedCrossRef

54.

Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de ZD, Pocock S, van Veldhuisen DJ (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113:671–678PubMedCrossRef

55.

Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, Nozaki N, Hirono O, Tsunoda Y, Nitobe J, Watanabe T, Kubota I (2007) High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 13:199–206PubMedCrossRef

56.

Koyama Y, Takeishi Y, Niizeki T, Suzuki S, Kitahara T, Sasaki T, Kubota I (2008) Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 14:133–139PubMedCrossRef

57.

Ljungman S, Laragh JH, Cody RJ (1990) Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 39(Suppl 4):10–21PubMedCrossRef

58.

Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD (2003) Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 18:892–898PubMedCrossRef

59.

Zoccali C, Mallamaci F, Tripepi G (2003) Inflammation and atherosclerosis in end-stage renal disease. Blood Purif 21:29–36PubMedCrossRef

60.

Gugliucci A, Bendayan M (1996) Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39:149–160PubMedCrossRef

61.

Hartog JW, Smit AJ, van Son WJ, Navis G, Gans RO, Wolffenbuttel BH, de Jong PE (2004) Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 43:966–975PubMedCrossRef

62.

Miyata T, Ueda Y, Horie K, Nangaku M, Tanaka S, Ypersele de Strihou C, Kurokawa K (1998) Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 53:416–422PubMedCrossRef

63.

Stenvinkel P, Alvestrand A (2002) Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15:329–337PubMedCrossRef

64.

Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R (2002) Advanced glycation end products activate endothelium through signal- transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105:816–822PubMedCrossRef

65.

Rader DJ (2000) Inflammatory markers of coronary risk. N Engl J Med 343:1179–1182PubMedCrossRef

66.

Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704–11708PubMedCrossRef

67.

Yamada K, Miyahara Y, Hamaguchi K, Nakayama M, Nakano H, Nozaki O, Miura Y, Suzuki S, Tuchida H, Mimura N (1994) Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 42:354–361PubMed

68.

Zoccali C, Mallamaci F, Tripepi G (2000) AGEs and carbonyl stress: potential pathogenetic factors of long-term uraemic complications. Nephrol Dial Transplant 15(Suppl 2):7–11PubMedCrossRef

69.

Hartog JW, de Vries AP, Lutgers HL, Meerwaldt R, Huisman RM, van Son WJ, de Jong PE, Smit AJ (2005) Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 1043:299–307PubMedCrossRef

70.

Al Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38:955–962PubMedCrossRef

71.

Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL (2007) Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9:872–878PubMedCrossRef

72.

Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW (2000) The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35:681–689PubMedCrossRef

73.

Hartog JW, Gross S, Oterdoom LH, van Ree RM, de Vries AP, Smit AJ, Schouten JP, Nawroth PP, Gans RO, van Son WJ, Bierhaus A, Bakker SJ (2009) Skin-autofluorescence is an independent predictor of graft loss in renal transplant recipients. Transplantation 87:1069–1077PubMedCrossRef

74.

Roberts MA, Thomas MC, Fernando D, Macmillan N, Power DA, Ierino FL (2006) Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant 21:1611–1617PubMedCrossRef

75.

Schwedler SB, Metzger T, Schinzel R, Wanner C (2002) Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62:301–310PubMedCrossRef

76.

Wagner Z, Molnar M, Molnar GA, Tamasko M, Laczy B, Wagner L, Csiky B, Heidland A, Nagy J, Wittmann I (2006) Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis 47:294–300PubMedCrossRef

77.

Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ (2005) Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16:3687–3693PubMedCrossRef

78.

Miyata T, van Ypersele dS (2003) Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 419:50–54PubMedCrossRef

79.

Monacelli F, Poggi A, Storace D, Durante A, Traverso N, Viviani GL, Odetti P (2006) Effects of valsartan therapy on protein glycoxidation. Metabolism 55:1619–1624PubMedCrossRef

80.

Saisho Y, Komiya N, Hirose H (2006) Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 74:201–203PubMedCrossRef

81.

Wagenaar LJ, Voors AA, Buikema H, van Gilst WH (2002) Angiotensin receptors in the cardiovascular system. Can J Cardiol 18:1331–1339PubMed

82.

Hartog JW, van de Wal RM, Schalkwijk CG, Miyata T, Jaarsma W, Plokker HW, van Wijk LM, Smit AJ, van Veldhuisen DJ, Voors AA (2010) Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. Eur J Heart Fail 12:397–403PubMedCrossRef

83.

Willemsen S, Hartog JW, Hummel YM, Posma JL, van Wijk LM, van Veldhuisen DJ, Voors AA (2010) Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. Eur J Heart Fail 12:294–300PubMedCrossRef

Title: Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome
Authors: Suzan Willemsen
Jasper W. L. Hartog
M. Rebecca Heiner-Fokkema
Dirk J. van Veldhuisen
Adriaan A. Voors
Publication date: 01-03-2012
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2012
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-010-9225-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis

Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes

New roles for renin and prorenin in heart failure and cardiorenal crosstalk

Atherosclerotic disease of the abdominal aorta and its branches: prognostic implications in patients with heart failure

Anemia in chronic heart failure: Can we treat? What to treat?

Cardio-renal syndromes: a systematic approach for consensus definition and classification

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page